Related Experiment Videos
Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach
1Boehringer Mannheim GmbH.
Insights
This study found that 25 mg of carvedilol once daily adequately treats patients. The dose-response curve for once-daily regimens shows optimal efficacy at 25 mg, with no added benefit from twice-daily dosing.
Area of Science:
- Pharmacology
- Clinical Trials
- Cardiovascular Medicine
Background:
- Establishing drug efficacy and safety necessitates unified methodological approaches and comprehensive analysis of all clinical trials.
- Carvedilol is an antihypertensive drug requiring thorough efficacy and safety evaluation.
Purpose of the Study:
- To present the aggregated dose-response relationship of efficacy data for carvedilol.
- To perform a last-value analysis of laboratory data across all carvedilol studies.
- To reanalyze all antihypertensive trials using an intent-to-treat principle.
Main Methods:
- Meta-analysis of aggregated efficacy data (mean, standard deviation, sample size) from clinical trials.
- Aggregation of laboratory data based on the last active drug.
- Calculation of hemodynamic and metabolic endpoints from baseline measurements.
Main Results:
- The patient population was adequately treated with 25 mg carvedilol once daily (o.d.).
- The dose-response curve for o.d. regimens exhibited a sigmoid shape, with a plateau after 25 mg.
- No significant superiority in blood pressure lowering was detected between once-daily (o.d.) and twice-daily (b.i.d.) dosing regimens.
Conclusions:
- 25 mg carvedilol o.d. is an effective dose for treating hypertension.
- Dosing frequency (o.d. vs. b.i.d.) did not significantly impact blood pressure reduction.
- Significant inter-study variability was observed, primarily attributed to monocentric trials.
Abstract:
Establishing the overall efficacy or safety of a drug requires a unified methodological approach and analysis of all clinical trials to be included. As an example, this paper presents the aggregated dose-response relationship of efficacy data and a last-value analysis of laboratory data across all studies of the antihypertensive drug project carvedilol. Hemodynamic endpoints were calculated as change from the baseline blood pressure and pulse after an average treatment of 2-4 weeks whereas metabolic endpoints were calculated as changes from the baseline until the last day with respect to glucose, potassium, creatinine, lipids and liver function (median duration of treatment was 8-12 weeks). All antihypertensive trials were reanalyzed using an intent-to-treat principle. Aggregated efficacy data (mean, standard deviation, sample size) for each allocated group within each study were combined by means of meta-analysis separately for o.d. or b.i.d. dose regimens. Laboratory data were aggregated similarly within each study, using the last active drug as a grouping factor. The results showed that the patient population was treated adequately with 25 mg carvedilol o.d. The dose response curve for o.d. regimens shows a typical sigmoid shape: a steeper increase from 12.5 mg to 25 mg carvedilol, which then flattens (25 mg, 50 mg, 100 mg carvedilol o.d.). No superiority of a b.i.d. dose regimen over a o.d. dose regimen by means of BP lowering could be detected. There was a considerable variation in the results between studies, much bigger than the dose-response effect, most due to monocentric trials.(ABSTRACT TRUNCATED AT 250 WORDS)